Organization
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
9 abstracts
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.Org: Bristol Myers Squibb, Cancer Research SA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institut Paoli-Calmettes, Marseille, France, Instituto Catalán de Oncología,
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,
Abstract
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.Org: Orlando Health Cancer Institute, First Department of Medicine, National and Kapodistrian University of Athens, Cooper University Hospital, Norris Comprehensive Cancer Center,
Abstract
A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors.Org: Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Washington University in St. Louis, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Beijing Biostar Pharmaceuticals, Biostar Pharma,
Abstract
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).Org: Mayo Clinic, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Atlantic Health System, Carol G Simon Cancer Center, Morristown, NJ, Department of Hematology and Oncology, Mayo Clinic Florida, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Abstract
Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute and Harvard Medical School, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Carbone Cancer Center, University of Wisconsin, Madison, WI, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL,
Abstract
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.Org: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, Beth Israel Deaconess Medical Center, Boston, MA,